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Significance of 
Pathophysiology
• Hypothesis of 
Hypodopaminergic 
Tone: inhibition of 
dopamine receptor 
activity in the CNS
(Belvederi Murri, 
Guaglianone, 
Bugliani, Calcagno, 
Respino, Serafini, & 
Amore, 2015) .
• Neuroleptic 
medications gain 
their therapeutic 
effect from blocking 
dopamine receptors.
• Usually develops 
within the first 2 
weeks of treatment, 
but can develop at 
any time during the 
therapy period (Gall-
Ojurongbe & 
Williams, 2015).  
• Occurs in all age 
groups; elderly may 
be at higher risk due 
to coexisting medical 
conditions; men 
affected = women 
affected; no genetic 
link (Waldorf, 2003).
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Figure 1: Genesis Theme Framework. Dopamine,
http://www.naturallivingideas.com/boost-
dopamine/
Conclusions
1). Muscular rigidity: ↓ 
dopamine in the 
nigrostriatal pathway 
(Waldorf, 2003).
Signs/Symptoms
2). Altered mental status: 
hyperpyrexia and ↓ 
dopamine in reticular 
activating system 
(Waldorf, 2003).
• Identified in France 
during the 1960’s as 
Syndrome Malin Des
Neuroleptiques (Gall-
Ojurongbe, & Williams, 
2015).
• NMS is a rare, life 
threatening reaction to 
antipsychotic therapy.
• Associated with 1st and 
2nd generation 
antipsychotics, atypical 
antipsychotics, and 
centrally acting 
antiemetic agents (Al 
Danaf, Madara, & 
Dietsche, 2015).
• Cardinal features: 1.
altered mental status 2. 
muscular rigidity 
3.hyperthermia, 4. 
dysautonomia (Drews & 
Evans, 2017). 
• Estimated incidence of 
0.02% to 3.23% (Wilson, 
Hayden, & Nordstrom, 
2016).
• Mortality rate 4%-30% 
(Waldorf, 2003).
3). Hyperthermia: ↓ 
dopamine in 
hypothalamus and 
overproduction of 
heat secondary to 
extreme muscle 
rigidity (Gall-
Ojurongbe &
Williams, 2015). 
4). Dysautonomia: 
dopamine receptor 
blockade in 
hypothalamus → 
instability (Waldorf, 
2003).
⃰ Decreased levels of Dopamine are 
responsible for the tetrad of cardinal
features presented in NMS.
• 2° signs/symptoms:  liver and kidney failure; 
hyperkalemia; leukocytosis; rhabdomyolysis; 
venous or arterial blood clots, acidosis, and 
hypoxia (Ojurongbe & Williams, 2015).
• Number of people taking 
antipsychotics/neuroleptic medications is 
on the rise.
• Advanced practice nurses (APNs) may be 
the one prescribing these medications 
and RN’s will be administering them → 
imperative to recognize the s/s associated 
with NMS.
• Important to know how to treat NMS:
• IMMEDIATELY stop 
medications
• Supportive care: control
temperature, restore
fluid/electrolyte balance, give a 
muscle relaxant such as 
Dantrolene, and stimulate 
dopamine production with 
Bromocriptine (Waldorf, 2003).
• EDUCATE EDUCATE EDUCATE!
• There is NO gold 
standard, diagnostic 
test available.
• NMS confirmed by 
clinical presentation, 
and exclusion of 
other causes.
• Differential
diagnostic 
considerations: 
Malignant 
Hyperthermia, 
pheochromocytoma, 
thyroid storm, 
serotonin syndrome, 
lethal catatonia, 
acute porphyria, 
tetany, encephalitis, 
brain lesions and 
tumors, sepsis, heat 
stroke, and drug use 
(Waldorf, 2003).
• Although the incidence of NMS is low, it 
may be fatal if early recognition is 
delayed!
• Can be difficult to Dx d/t multiple
complicating and confusing factors
associated with its presentation.
• Knowledge of pharmacology, a good 
history of medication use, and quick 
identification of s/s in mild cases can 
prevent occurrence and              
progression to  lethal                    
outcomes (Belvederi Murri,                       
et al., 2015).  
• Goal = ↓ mortality                                      
Figure 2: Internal Medicine: A Guide to Clinical Therapeutics,
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